FDA grants Breakthrough Therapy designation to Simcere's Sanbexin Sublingual Tablets for stroke treatment.
Simcere Pharmaceuticals Group Ltd. has received Breakthrough Therapy designation from the FDA for its Sanbexin Sublingual Tablets, the first drug of its kind for stroke treatment. This designation aims to expedite development for serious conditions. Sanbexin, which combines edaravone and dexborneol, shows promise in improving outcomes for patients with acute ischemic stroke, the most common stroke type, impacting millions globally each year.
September 14, 2024
5 Articles